PFE heads into Q4 earnings with strong oncology and Vyndaqel demand, but IRA headwinds, COVID declines and falling estimates ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?